Skip to main content

Octerotide for bowel obstructions | IMPACCT Trials Coordination Centre

A randomised, double-blind, placebo-controlled trial of infusional subcutaneous octreotide in the management of malignant bowel obstruction in people with advanced cancer.

DOI10.58084/fv1e-ac81
Type of DOIdataset
PublisherPalliative Care Clinical Studies Collaborative (PaCCSC)
CreatorsProfessor David Currow
Date made available2024
Description of dataset

Data set includes

  • individual participant data for 112 consenting participants
  • CSV files for the number of days free of vomiting as reported by patients daily, measured 72 hours after the first administration of study medication
  • patient-rated Global Impression of Change
  • the number of patient-reported episodes of vomiting
  • survival as date of death
  • nausea and Pain scores using NCI CTCAE criteria and Brief Pain Inventory
  • functional status (Australian modified Karnofsky Performance Scale (AKPS)
  • protocol defined “as needed” symptom control medications (hyoscine butylbromide for colicky pain, morphine for pain, haloperidol for nausea)
  • quality of life measures used the EORTC C15, Facit Pal
  • caregiver quality of life was measured using the Caregiver Quality of Life Index
  • data is available for screening, baseline, each day of intervention, and four weeks of follow up
  • health service utilisation data was collected for up to 4 weeks post intervention.
FundingAustralian Government
Subject (ANZCTR category)Gastroenterology and hepatology
ANZCTR referenceACTRN12621001403820
Main trial pagePaCCSC clinical trials
Publications

Clinician-reported changes in octreotide prescribing for malignant bowel obstruction as a result of an adequately powered phase III study: A transnational, online survey

Double-blind, placebo-controlled, randomized trial of octreotide in malignant bowel obstruction 

Octreotide for Malignant Bowel Obstruction: Commentary on Currow et al

Dataset accessAccess can be requested via the Health Data Australia catalogue. Search for the ACTRN number in the catalogue to find datasets associated with these trials or email enquiries to hesanda@uts.edu.au.